Study: NCT01273064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: 180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: 180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: 180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon
Description: 180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo).